Visiongain Report Looks at Opportunities Within the $257bn Rare Disease Drugs Market

News provided by

07 Oct, 2019, 09:00 GMT

- Global Rare Disease Drugs Market Forecast 2019-2029

- Oncology, Metabolic Diseases, Neurologic Diseases, Haematology Diseases, Infectious Diseases, Specialty Pharmacies, Hospital Pharmacies, Retail Pharmacies

LONDON, Oct. 7, 2019 /PRNewswire/ -- The global rare disease drugs market is estimated to reach $257bn in 2024 and is expected to grow at a CAGR of 11.3% throughout the forecast period. In 2018, rare oncology diseases segment held 36% of share in the global rare disease drugs market.

How this report will benefit you
Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 250-page report you will receive 145 charts– all unavailable elsewhere.

The 250-page report provides clear detailed insight into the global rare disease drugs market. Discover the key drivers and challenges affecting the market.

By ordering and reading Visiongain's brand-new report today you stay better informed and ready to act.

To request sample pages from this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-rare-disease-drugs-market-forecast-2019-2029/#download_sampe_div

Report Scope

• Global Rare Disease Drugs Market forecasts from 2019-2029

• Revenue forecasts for the global rare disease drugs market by application from 2019-2029:
• Rare Oncology Diseases
• Rare Metabolic Diseases
• Rare Neurologic Diseases
• Rare Hematology Diseases
• Rare Infectious Diseases
• Other Rare Diseases

• Revenue forecasts for the global rare disease drugs market by distribution channel from 2019-2029:
• Specialty Pharmacies
• Hospital Pharmacies
• Retail Pharmacies

• Revenue forecasts for the global rare disease drugs market by drug from 2019-2029:
• Avonex
• Copaxone
• Gleevec
• Imbruvica
• MabThera/Rituxan
• Opdivo
• Rebif
• Revlimid
• Sprycel
• Tasigna
• Velcade
• Other Drugs

• Revenue forecasts for the rare disease drugs market by Regional and National Market from 2019-2029:
• North America (US, Canada)
• Europe (Germany, UK, France, Italy, Spain)
• Asia-Pacific (Japan, China, India, South Korea)
• RoW (Brazil, Mexico, South Africa, Russia)

• Profiles and discussion on the leading companies in the rare disease drugs market:
• AbbVie
• Bristol-Myers Squibb (BMS)
• Celgene
• Merck & Co., Inc.
• Novartis
• Pfizer
• Roche
• Sanofi
• Takeda
• Teva

• Rare disease drugs pipeline analysis covering rare oncology drugs, rare autoimmune disease drugs, blood-related rare disease drugs, rare genetic disease drugs and rare infectious disease drugs.

• SWOT Analysis and Porter's Five Forces analysis of the global rare disease drugs market

• Discussion on factors that drive and restrain the global rare disease drugs market as well as opportunities in this market.

• Key Questions Answered by this Report:
• What are the global revenue prospects for the period 2019 to 2029?
• What are the leading national market potentials from 2019 to 2029?
• How is the rare disease drugs market evolving?
• What is driving and restraining the rare disease drugs market?
• What are the market shares of each segment of the overall rare disease drugs market?
• How will main rare disease drugs submarket segments develop over the forecast period and how much revenue will these submarkets account for in 2029?
• How will the market shares for each rare disease drugs submarket develop from 2018 to 2029?
• Which therapies can succeed and what revenues could they generate to 2029?
• What will be the main commercial drivers for the market from 2018 to 2029?
• How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
• How will that industry evolve between 2018 and 2029, especially in R&D?

To request a report overview of this report please contact Sara Peerun at sara.peerun@visiongain.com or refer to our website: https://www.visiongain.com/report/global-rare-disease-drugs-market-forecast-2019-2029/

Did you know that we also offer a report add-on service? Email sara.peerun@visiongain.com to discuss any customized research needs you may have.

Companies covered in the report include:

AB Science
AbbVie
Acceleron Pharma & Celgene
Acer Therapeutics
Actavis Generics
Actelion Pharmaceuticals
Actinium Pharmaceuticals
Adaptimmune
Aduro BioTech
Advanced Accelerator Applications
Advantagene
Advaxis
Advenchen Laboratories
Affimed Therapeutics & Merck
Agenus
Agios Pharmaceuticals
Akashi Therapeutics
Akcea Therapeutics
Alcobra
Alexion Pharmaceuticals
Alkeus Pharmaceuticals
Allergan
Alnylam Pharmaceuticals
Ambit Biosciences
AmerisourceBergen Corporation
Amgen
Amicus Therapeutics
Andarix Pharmaceuticals
Angimmune
Angiochem
AntiVirus Therapeutics
Applied Genetic Technologies
Araim Pharmaceuticals
Arch Biopartners
arGentis Pharmaceuticals
ARIAD Pharmaceuticals
ArmaGen Technologies
ARMGO Pharma
AROG Pharmaceuticals
ArQule
ArQule
Array BioPharma
Arrowhead Research
Astellas Pharma US
Astex Pharmaceuticals
AstraZeneca
ATARA Biotherapeutics
Atox Bio
aTyr Pharma
Baxalta
Bayer HealthCare Pharmaceuticals
Belrose Pharmaceuticals
BerGenBio
BioBlast Pharma
BioCryst Pharmaceuticals
Biodel
Biogen
BioInvent International
BioLineRx
BioMarin Pharmaceutical
BioNTech
Bio-Path Holdings
Biotest Pharmaceuticals
Blaze Bioscience
bluebird bio
Blueprint Medicines
Boehringer Ingelheim Pharmaceuticals
Bristol-Myers Squibb
Burzynski Research Institute
Caladrius Biosciences
Cancer Advances
Cancer Prevention Pharmaceutical
Capricor Therapeutics
Cardinal Health, Inc.
CASI Pharmaceuticals
Catabasis Pharmaceuticals
Cavion
Celator Pharmaceuticals
Celgene Corporation
Cell Medica
Cell Therapeutics
Cellectar Biosciences
CEL-SCI
Celsion
Celtaxsys
Cempra Pharmaceuticals
CerRx
Cerulean Pharma
ChemoCentryx
Chugai Pharma
Cidara Therapeutics
Cleave Biosciences
Clementia Pharmaceuticals
Clinuvel
Clovis Oncology
Confluence Pharmaceuticals
Corbus Pharmaceuticals
Cornerstone Pharmaceuticals
Cortice Biosciences
Critical Outcome Technologies
Curis
Cyclacel
CymaBay Therapeutics
CytRx
Daiichi Sankyo
Deciphera Pharmaceuticals
Delcath Systems
DelMar Pharmaceuticals
Diffusion Pharmaceuticals
Dimension Therapeutics
Diurnal
DNAtrix
Eddingpharm
Edimer Pharmaceuticals
Edison Pharmaceuticals
Eiger Biopharmaceuticals
Eisai
Eleison Pharmaceuticals
Eli Lilly
EMD Serono & Pfizer
Emergent BioSolutions
Emmaus Medical
Epitopoietic Research
Epizyme
Epizyme
EryDel
Escala Therapeutics
Essentialis
Five Prime Therapeutics
Fortress Biotech
Gamida Cell
Gem Pharmaceuticals
Gen Sight Biologics
Genentech
GenSpera
Genzyme
Gilead Sciences
GlaxoSmithKline
Gliknik
Global Blood Therapeutics
GlycoMimetics
Golden Biotechnology
Gradalis
Grifols Therapeutics
GW Pharma
Halozyme Therapeutics
Hanmi
Hoffmann-La Roche Ltd
Horizon Pharma
Idera Pharmaceuticals
Ignyta
Immatics Biotechnologies
Immune Design
Immune Pharmaceuticals
Immune Response BioPharma
Immune Therapeutics
ImmunoCellular Therapeutics
ImmunoGen
Immunomedics
Immunovaccine Technologies
Incyte
Infinity Pharmaceuticals
InnoPharma
Insmed
Insys Therapeutics
Ionis Pharmaceuticals
Ionis Pharmaceuticals
Ipsen Biopharmaceuticals
IRX Therapeutics
Janssen Biotech
jCyte
Juno Therapeutics
Karyopharm Therapeutics
Kevelt
Kyowa Kirin USA
LeafBio
Lexicon Pharmaceuticals
Lion Biotechnologies
LipimetiX Development
MabVax Therapeutics
Marathon Pharmaceuticals
Marina Biotech
Mast Therapeutics
McKesson Corporation
MedImmune
MEI Pharma
Merck & Co., Inc
Millendo Therapeutics
Millennium Pharmaceuticals
Milo Biotechnology
Minneamrita Therapeutics
Mirati Therapeutics
Momenta Pharmaceuticals
MorphoSys
Nektar Therapeutics
NeOnc Technologies
Neuren Pharmaceuticals
Neurolixis
Neurotech USA
NGM Biopharmaceuticals
NightstaRx
Nivalis Therapeutics
NKT Therapeutics
Novartis Pharmaceuticals
Novo Nordisk
Novoteris
Ocata Therapeutics
Omeros
On Target Laboratories
Oncolix
Oncolytics Biotech
OncoMed Pharmaceuticals
OncoMed Pharmaceuticals & GlaxoSmithKline
Onconova Therapeutics
OncoPep
Oncopeptides
OPKO Biologics
OSE Pharma
Otsuka Pharmaceutical
OXiGENE
Patagonia Pharmaceuticals
Peregrine Pharmaceuticals
Pfizer Inc.
Pharmacyclics
PharmaCyte Biotech
PharmaEssentia, Corporation
PharmaMar USA
Plexxikon
PNP Therapeutics
Polaris Pharmaceuticals
Polynoma
Prana Biotechnology
Precision Biologics
Progenics Pharmaceuticals
Prolong Pharmaceuticals
Promedior
ProMetic Biotherapeutics
ProNAi Therapeutics
ProQR Therapeutics
Protalex
Provectus Pharmaceuticals
PTC Therapeutics
QLT
Quest PharmaTech
Qurient
Raptor Pharmaceutical
Rebiotx
Regeneron Pharmaceuticals
Regulus Therapeutics & Sanofi US
Retrophin
RetroSense Therapeutics
ReveraGen Biopharma
Rexahn Pharmaceuticals
Rhythm Metabolics
Rigel Pharmaceuticals
River Vision
Roche
Sanofi S. A.
Santhera Pharmaceuticals
Sarepta Therapeutics
Savara Pharmaceuticals
Seattle Genetics
Selexys Pharmaceuticals
SELLAS Life Sciences
Sequella
Seres Health
Shire plc
SIGA Technologies
Sigma-Tau Pharmaceuticals
SillaJen Biotherapeutics
Soligenix
Soricimed Biopharma
Spark Therapeutics
StemcentRx
Stemline Therapeutics
Sun BioPharma
Sun Pharmaceuticals
Sunesis Pharmaceuticals
Takeda Pharmaceuticals
Tapimmune
Tarix Orphan
TESARO
TetraLogic Pharmaceuticals
Teva Pharmaceutical
TG Therapeutics
Tiziana Life Sciences
Tocagen
Tolero Pharmaceuticals
Tracon Pharmaceuticals
TransDerm
Triphase Research & Development
Triphase Research and Development
Ultragenyx Pharmaceutical
Ultragenyx Pharmaceutical
uniQure
UroGen
Vascular Biogenics
VentiRx Pharmaceuticals
Verastem
Vertex Pharmaceuticals
Viamet Pharmaceuticals
Vicus Therapeutics
Viralytics
Viventia Biotech
VivoLux
Vtesse
Wilson Therapeutics
Xeris Pharmaceuticals
XOMA
Ziopharm Oncology
Zogenix
Zywie